Tomas Kiselak, Director, 10% Owner at Dianthus Therapeutics, Inc. /DE/ (DNTH), bought 30,000 shares at $13.20 ($396K) on 2023-09-19, disclosed to the SEC on 2023-09-21.
Open-market purchase of $396k DNTH by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |